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ABSTRACT: OXA-163 and OXA-48 are closely related class
D β-lactamases that exhibit diﬀerent substrate proﬁles. OXA-
163 hydrolyzes oxyimino-cephalosporins, particularly ceftazi-
dime, while OXA-48 prefers carbapenem substrates. OXA-163
diﬀers from OXA-48 by one substitution (S212D) in the
active-site β5 strand and a four-amino acid deletion (214-
RIEP-217) in the loop connecting the β5 and β6 strands.
Although the structure of OXA-48 has been determined, the
structure of OXA-163 is unknown. To further understand the
basis for their diﬀerent substrate speciﬁcities, we performed
enzyme kinetic analysis, inhibition assays, X-ray crystallography, and molecular modeling. The results conﬁrm the carbapenemase
nature of OXA-48 and the ability of OXA-163 to hydrolyze the oxyimino-cephalosporin ceftazidime. The crystal structure of
OXA-163 determined at 1.72 Å resolution reveals an expanded active site compared to that of OXA-48, which allows the bulky
substrate ceftazidime to be accommodated. The structural diﬀerences with OXA-48, which cannot hydrolyze ceftazidime, provide
a rationale for the change in substrate speciﬁcity between the enzymes. OXA-163 also crystallized under another condition that
included iodide. The crystal structure determined at 2.87 Å resolution revealed iodide in the active site accompanied by several
signiﬁcant conformational changes, including a distortion of the β5 strand, decarboxylation of Lys73, and distortion of the
substrate-binding site. Further studies showed that both OXA-163 and OXA-48 are inhibited in the presence of iodide. In
addition, OXA-10, which is not a member of the OXA-48-like family, is also inhibited by iodide. These ﬁndings provide a
molecular basis for the hydrolysis of ceftazidime by OXA-163 and, more broadly, show how minor sequence changes can
profoundly alter the active-site conﬁguration and thereby aﬀect the substrate proﬁle of an enzyme.
β-Lactams are the most commonly prescribed antibiotics
worldwide.1 Therefore, bacterial resistance toward these drugs
presents a serious public health threat.2,3 The eﬀectiveness of β-
lactam antibiotics is challenged by the emergence of multidrug
resistant Gram-negative bacteria from the Enterobacteriaceae
family such as Klebsiella pneumoniae.4−7 The most common
mechanism of β-lactam antibiotic resistance in Gram-negative
pathogens is the production of β-lactamases that hydrolyze and
inactivate the drugs.8−11 β-Lactamases are divided into four
classes (A−D) based on amino acid sequence homology.12
Class A, C, and D enzymes are serine hydrolases, while
members of class B are metallo-β-lactamases that are unrelated
in sequence and mechanism to the other classes.12,13 In recent
years, β-lactamase variants from classes A and D with the ability
to hydrolyze oxyimino-cephalosporins and carbapenems have
emerged. This alarming trend is reducing the number of
treatment options because oxyimino-cephalosporins are regu-
larly prescribed, while carbapenems are considered last resort
options in the treatment of multidrug resistant infections.14−17
The class D β-lactamases (DBLs) are the most diverse group
among serine β-lactamases, with certain members possessing
<20% sequence identity.18,19 Despite their sequence diversity,
DBLs have conserved structural features that are involved in the
mechanism of hydrolysis. The mechanism of hydrolysis of β-
lactam antibiotics by DBLs involves acylation and deacylation
of the active-site serine and features a carboxylated lysine as the
general base.20,21 This reversible lysine modiﬁcation, which is
essential for DBL activity, is proposed to be a spontaneous
reaction, facilitated by the hydrophobic environment of the
active site and dependent on the protonation state of the lysine
and the availability of CO2.
17,20,22 Another property of DBLs
that is not shared by other serine β-lactamases is inhibition by
sodium chloride in vitro.18 Most DBLs are fully inhibited at a
sodium chloride concentration of 100 mM.23 This property is
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not fully understood, but a tyrosine residue, which is a
constituent of a conserved YNG motif located in the vicinity of
the DBL active site, has been implicated.24 Heŕitier et al.
showed that when the active-site tyrosine is substituted with
phenylalanine, the resulting mutant is resistant to sodium
chloride inhibition. Additionally, the mutant enzyme exhibited
weaker activity for all the substrates tested.24 A more recent
study suggests that chloride competes with the carboxylation of
the lysine and thereby inhibits DBLs by attenuating formation
of the general base.25
DBLs are also called oxacillinases (or OXA-enzymes) on the
basis of the properties of the ﬁrst discovered members of this
class, which have high catalytic eﬃciency for the hydrolysis of
the semisynthetic penicillin oxacillin.26 The rapid discovery of
DBLs in recent years has led to the description of more than
400 OXA-enzymes.27−30 On the basis of substrate speciﬁcity,
they can be classiﬁed as narrow-spectrum oxacillinases,
extended-spectrum β-lactamases (ESBLs), or carbapenem-
hydrolyzing class D β-lactamases (CHDLs).17,18,27,31 Further-
more, to better separate the OXA-enzymes, several subgroups
have been formed on the basis of sequence homology. The
enzymes within a subgroup diﬀer from each other by one to ﬁve
amino acids on average and generally have similar kinetic
proﬁles.
OXA-48-like β-lactamases constitute a CHDL subgroup that
is widespread in K. pneumoniae and other Enterobacteria-
ceae.28,32 Their emergence represents an alarming development
in carbapenem resistance worldwide. OXA-48, which was the
ﬁrst OXA-type carbapenemase isolated from enteric bacteria,
has been identiﬁed for more than a decade from a multidrug
resistant K. pneumoniae isolate, and it is the most widespread
member of this subgroup.28,33 It has a typical carbapenemase
substrate proﬁle with the highest catalytic eﬃciency for
imipenem hydrolysis among all DBLs. However, its activity
for oxyimino-cephalosporins is very modest and, in the case of
ceftazidime, undetectable.33,34 Currently, the OXA-48-like
subgroup has 11 members, and they diﬀer from OXA-48 by a
few amino acid substitutions and deletions.32 All of the OXA-
48-like enzymes have substrate proﬁles similar to that of OXA-
48 except for OXA-163.32 The OXA-163 enzyme has a
drastically reduced ability to hydrolyze carbapenems; however,
unlike OXA-48, OXA-163 is able to hydrolyze the oxyimino-
cephalosporin ceftazidime.35
OXA-163 is a relatively new β-lactamase that was identiﬁed
in K. pneumoniae and Enterobacter cloacae from nosocomial
infections.35 OXA-163 diﬀers from OXA-48 by an S212D
substitution and a four-amino acid deletion (214-RIEP-217)
(OXA-48 numbering).34−36 The S212D substitution is located
at the tip of the β5 strand, and the four-amino acid deletion is
located in the loop region between the β5 and β6 strands.34
The β5 strand forms one side of the active-site cavity and
contains the conserved K(S/T)G motif (residues 208−210)
typical for DBLs.34 The loop between the β5 and β6 strands has
been suggested to be important for the ability of an OXA
variant to hydrolyze carbapenems, and therefore, the deletion
may impact carbapenem hydrolysis.34,37−39
The goal of this study was to determine the structural basis
for the change in substrate speciﬁcity observed in OXA-163
versus OXA-48. The crystal structure of OXA-163 determined
at 1.72 Å resolution revealed that the four-amino acid deletion
in OXA-163 expands the active-site pocket to accommodate the
bulky side chain of ceftazidime, providing a molecular basis for
the diﬀerent substrate proﬁles of the two enzymes. Additionally,
a second structure of OXA-163 was determined at 2.87 Å
resolution using crystals from a diﬀerent crystallization
condition. This crystallization buﬀer contained iodide, which
was found in the active site of the enzyme in the structure.
Subsequent enzyme inhibition assays indicated that iodide is an
inhibitor of both OXA-163 and OXA-48 as well as OXA-10,
which is not in the OXA-48-like family. On the basis of the
structural and inhibition analyses, it is proposed that halogen
ions inhibit OXA-enzymes by changing the position of key
active-site residues and inhibiting the formation of the
carboxylated lysine, which is essential for the function of all
OXA-enzymes.
■ MATERIALS AND METHODS
Cloning. The blaOXA‑163 gene containing the native signal
sequence was inserted into the EcoRI site of the pET29a
expression vector using T4 DNA ligase (New England Biolabs,
Ipswich, MA). The blaOXA‑48 gene in the pET29a plasmid was
constructed by introducing the D212S substitution and 214-
RIEP-217 insertion into the blaOXA‑163 gene by QuikChange
polymerase chain reaction with Pfu Turbo DNA Polymerase
(Agilent, Santa Clara, CA). The DNA sequence encoding the
mature portion of blaOXA‑10 was introduced into the pET28a
vector using a Gibson assembly kit (New England Biolabs) with
ﬂanking NdeI and SacI restriction sites that also contained an
N-terminal His tag. DNA sequencing of the entire genes
veriﬁed the sequences of blaOXA‑163, blaOXA‑48, and blaOXA‑10.
Protein Expression and Puriﬁcation. OXA-48 and OXA-
163 were expressed following a protocol previously described
by Sosa-Peinado et al.40 In brief, cells were grown in 1 L of LB
broth containing 300 mM sorbitol, 2.5 mM betaine, and 30 μg/
mL kanamycin to an OD600 of 0.6−0.8 before induction with
0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The
culture was then incubated at 23 °C for 20 h while being
shaken. Afterward, the culture was centrifuged for 40 min at
7000g, and the supernatant was concentrated 10-fold using
Vivaﬂow50 10MWCO (Sartorius, Goettingen, Germany)
following dialysis (1:50) overnight at 4 °C against buﬀer
containing 20 mM Tris and 0.4 M NaCl (pH 8.2). The proteins
were puriﬁed to ∼95% homogeneity using a Fast Flow
Chelating Sepharose (GE Healthcare, Pittsburgh, PA) packed
in a column with a 16 mm diameter and a 170 mm bed length,
loaded with zinc, and eluted with a linear gradient of 150 mM
imidazole. Purity was determined by sodium dodecyl sulfate−
polyacrylamide gel electrophoresis (SDS−PAGE), and protein
fractions were concentrated with Vivaspin Turbo centrifugal
ﬁlters 10MWCO (Sartorius). After concentration, size-
exclusion chromatography using a HiLoad 16/600 Superdex
75 column (GE Healthcare) was performed in 10 mM Tris
(pH 7.7) and 50 mM NaCl. Size-exclusion chromatography of
both OXA-48 and OXA-163 indicated the presence of a
dimer.34 Fractions were concentrated, and the protein
concentration was determined by absorbance measurements
at 280 nm using an extinction coeﬃcient of 63940 M−1 cm−1.41
OXA-10 was expressed and puriﬁed as follows. LB medium
(0.5 L) supplemented with 30 μg/mL kanamycin was
inoculated with 10 mL of overnight culture of Escherichia coli
BL21(DE3) carrying the pET28a-blaOXA‑10 plasmid. Protein
production was induced with 0.5 mM IPTG when the cell
culture reached an OD600 of 0.8. The culture was then
incubated at 30 °C for 20 h. Afterward, the culture was
centrifuged for 40 min at 7000g. The cell pellet was
resuspended in 20 mL of lysis buﬀer containing 50 mM
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phosphate (pH 7.4), 40 μMMgCl2, and 10 ng/mL DNase. Cell
contents were released using a French press, and the lysate was
centrifuged at 10000g for 30 min. The supernatant was passed
through a HisTrap FF column (GE Healthcare), and the
protein was eluted with a linear gradient of 500 mM imidazole.
Protein was concentrated by buﬀer exchange using Vivaspin
Turbo centrifugal ﬁlters 10MWCO (Sartorius). Protein purity
was determined by SDS−PAGE. The protein concentration
was determined by absorbance measurements at 280 nm using
an extinction coeﬃcient of 47565 M−1 cm−1. The N-terminal
His tag was not removed because steady-state kinetics of the
His-OXA-10 enzyme conﬁrmed that activity is not aﬀected by
the tag (data not shown).
Enzyme Kinetic Studies. Assays were performed on a
DU800 spectrophotometer at 30 °C in 50 mM sodium
phosphate buﬀer (pH 7.2) supplemented with 15 mM sodium
bicarbonate as previously described.42 Substrate hydrolysis was
followed at wavelengths of 260 nm for ceftazidime (Δε =
−6900 M−1 cm−1) and cefotaxime (Δε = −7500 M−1 cm−1),
262 nm for cephalothin (Δε = −7660 M−1 cm−1), 298 nm for
meropenem (Δε = −7200 M−1 cm−1), and 299 nm for
imipenem (Δε = −9670 M−1 cm−1), doripenem (Δε = −11540
M−1 cm−1), and nitroceﬁn (Δε = 20500 M−1 cm−1). Enzyme
kinetic data was analyzed with GraphPad Prism 6 (GraphPad
Software, Inc., La Jolla, CA) and ﬁtted to the Michaelis−
Menten equation. In the cases in which Vmax could not be
reached because of a high Km value, the catalytic eﬃciency
(kcat/Km) was calculated by ﬁtting the data to a ﬁrst-order
kinetics equation.43 Inhibition by halogen ions was examined
with NaI, NaBr, NaCl, or NaF using cephalothin (50 μM for
OXA-48 and 12 μM for OXA-10) and 13 μM cefotaxime
(OXA-163) as substrates in 50 mM sodium phosphate buﬀer
(pH 7.2). The enzymes were preincubated with increasing
concentrations of inhibitor for 30 min at room temperature and
for an additional 10 min at 30 °C before hydrolysis was
monitored. The concentration that reduced the level of
hydrolysis by 50% (IC50) was determined.
44
Crystallization and Data Collection. Crystal conditions
were screened with 10 mg/mL concentrated protein using a
range of commercially available screens. OXA-163 crystals grew
in 0.1 M HEPES (pH 7.7) and 14% (w/v) PEG 8000. Crystals
were cryoprotected with the well solution containing 20% (v/v)
PEG 600 and ﬂash-frozen in liquid nitrogen. A 1.72 Å
resolution data set was collected on beamline 5.0.1 of the
Berkeley Center for Structural Biology in the context of the
Collaborative Crystallography Program. Another crystallization
condition was identiﬁed containing 0.2 M NaI (pH 5.5) and
15% PEG 3350. Crystals were cryoprotected with the well
solution containing 30% glycerol. A 2.87 Å data set was
collected at the Baylor College of Medicine on a Rigaku FR-E
SuperBright High-Brilliance Rotating Anode Generator.
Structure Determination and Reﬁnement. Diﬀraction
data were processed using the CCP4i suite.45 iMOSFLM was
used to process and integrate the images.46 The crystal
structures were determined by molecular replacement using
OXA-48 [Protein Data Bank (PDB) entry 3HBR] as the
phasing model with MOLREP.47 After one round of
REFMAC5 reﬁnement, AutoBuild was used (Phenix suite)
followed by manual inspection with COOT.48−50 Several cycles
of reﬁnement were performed using phenix.reﬁne (native) and
REFMAC5 (with iodide).51,52 The presence of iodide was
conﬁrmed by computing the anomalous diﬀerence map using
the data set without averaging the Friedel pair intensities (Rmeas
= 13.3%). Data collection and reﬁnement statistics are listed in
Table 1.
Molecular Docking. Docking experiments were performed
with cefotaxime (PDB ligand id CE3) and ceftazidime.
Ceftazidime (CID481173) coordinates were retrieved from
the PubChem compound database.53 The substrate molecule
was docked into the crystal structure of OXA-48 (PDB entry
3HBR) and OXA-163 (PDB entry 4S2L) using AutoDock Vina
(The Scripps Institute, La Jolla, CA).54 Before being docked,
the proteins were processed by adding polar hydrogen atoms
using AutoDockTools. The Lamarckian genetic algorithm was
used to generate possible protein−ligand binding conforma-
tions.55 The receptor (β-lactamase) was treated as a rigid body,
with all possible rotational angles in the substrate. The grid box
was centered on the Ser70 residue with the size (22 Å × 24 Å ×
Table 1. Data Collection and Reﬁnement Statistics
OXA-163 (PDB entry
4S2L)
OXA-163 (PDB entry
4S2M)
Data Collection
wavelength (Å) 0.997 1.54
resolution range
(Å)
38.2−1.72 (1.78−1.72) 61.77−2.87 (2.98−2.87)
space group P21 P1
unit cell
dimensions
a, b, c (Å) 44.9, 125.8, 49.7 67.6, 68.4, 70.2
α, β, γ
(deg)
90.0, 116.8, 90.0 62.2, 68.0, 71.6
no. of unique
reﬂections
51864 (5184) 22060 (2111)
multiplicity 10.4 (10.3) 8.2 (7.9)
completeness
(%)
99.7 (99.8) 95.0 (90.3)
mean I/σ(I) 52.5 (3.40) 5.1 (2.0)
Wilson B factor
(Å2)
18.3 58.8
Rmerge (%) 7.7 (53) 9.3 (32.5)
Reﬁnement
Rwork (Rfree) (%) 19.5 (23.7) 20.1 (25.6)
no. of non-
hydrogen atoms
4642 7752
protein 3883 7661
ligands 20
waters 759 71
no. of protein
residues
474 935
root-mean-
square deviation
for bond lengths
(Å)
0.009 0.013
root-mean-
square deviation
for bond angles
(deg)
1.18 1.49
Ramachandran
favored
(%)
95 96
outliers
(%)
0 0.33
average B factor
(Å2)
22.9 55.5
protein 21 55.6
ligands − 80.9
waters 32.8 30.4
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24 Å) of the box adjusted to cover the entire catalytic site.
Docking was conducted with an exhaustiveness of 8.
PDB Accession Codes and Programs Used. The atomic
coordinates of the OXA-163 structure were deposited in the
Protein Data Bank56 as entries 4S2L (native) and 4S2M (with
iodide). Alignment and root-mean-square deviation (rmsd)
calculations were performed by the SSM procedure using
COOT.57 All structural ﬁgures were generated with UCSF
Chimera.58
■ RESULTS AND DISCUSSION
Enzyme Kinetic Parameters of OXA-48 and OXA-163
for Cephalosporins and Carbapenems. To examine if the
changes in sequence result in diﬀerent substrate speciﬁcity
between OXA-48 and OXA-163, steady-state kinetic parame-
ters were determined for several clinically used cephalosporin
and carbapenem substrates as well as the colorimetric
cephalosporin, nitroceﬁn. For OXA-48, the highest catalytic
eﬃciency is observed for nitroceﬁn hydrolysis (4.0 × 106 s−1
M−1) (Table 2). With regard to clinically relevant substrates,
however, the results conﬁrm that OXA-48 has a preference for
carbapenems, with the highest catalytic eﬃciency (kcat/Km)
observed for imipenem hydrolysis (9.0 × 105 s−1 M−1).33,34
Compared to imipenem, the OXA-48 kcat/Km value is 53-fold
smaller for meropenem and 56-fold smaller for doripenem
hydrolysis because of a reduction in the turnover number (kcat).
In addition, the early cephalosporin, cephalothin, is hydrolyzed
with a kcat/Km slightly higher than that of the oxyimino-
cephalosporin cefotaxime mainly because of a lower Km value.
Finally, the steady-state kinetic analysis indicates OXA-48 does
not hydrolyze the bulky oxyimino-cephalosporin ceftazi-
dime.33,59
The substrate proﬁle of OXA-163 is substantially diﬀerent
from that of OXA-48. Unlike OXA-48, OXA-163 has a
preference for cephalosporin substrates (Table 2). The highest
kcat/Km values were observed for nitroceﬁn (1.8 × 10
6 s−1 M−1),
cephalothin (5.0 × 105 s−1 M−1), and cefotaxime (3.8 × 105 s−1
M−1). Ceftazidime was hydrolyzed with the lowest kcat/Km (300
s−1 M−1) among the cephalosporins tested because of a high Km
value. Nevertheless, OXA-163 does hydrolyze ceftazidime. The
carbapenemase activity of OXA-163 is attenuated largely
because of a reduction in the turnover number, while the
aﬃnity is very similar to the aﬃnity of OXA-48 for
carbapenems. This leads to a decrease of 820-fold in the
catalytic eﬃciency of OXA-163 for imipenem in comparison to
that of OXA-48. However, it is noteworthy that the catalytic
eﬃciencies of OXA-163 are higher for meropenem and
doripenem than for imipenem, which is the opposite of that
observed for OXA-48. This change in order of preference is due
to a larger reduction in kcat for imipenem hydrolysis compared
to those of meropenem and doripenem in the OXA-163
enzyme (Table 2). Although the reason for this cannot be
known without further structural data, it is possible that the
smaller size of imipenem in comparison to meropenem and
doripenem allows it to ﬁt better in the active site of OXA-48,
leading to a higher rate of turnover of imipenem by OXA-48,
which is then lost due to the active-site expansion that occurs in
OXA-163 as described below.
In summary, the results conﬁrm the ability of the OXA-48
active site to accommodate carbapenem substrates, particularly
imipenem, while it is unable to hydrolyze ceftazidime, a bulkier
oxyimino-cephalosporin.34,35 When OXA-48 is transformed to
OXA-163 by mutations, it loses its high catalytic eﬃciency for
carbapenems, particularly imipenem, but gains the ability to
hydrolyze ceftazidime. Therefore, the 214-RIEP-217 deletion
and S212D substitution alter the substrate speciﬁcity of the
enzyme. This ﬁnding is consistent with previously published
kinetic data showing a signiﬁcant increase in the level of
ceftazidime hydrolysis compared to that of OXA-48.34,35
Additionally, two other members of the OXA-48-like β-
lactamases, OXA-24760 and OXA-405, which diﬀer from
OXA-48 by a four-amino acid deletion, 214-RIEP-218 and
213-TRIE-217, respectively, have signiﬁcantly lowered activity
toward carbapenem substrates compared to that of OXA-48 (P.
Nordmann, personal communication).
1.72 Å Crystal Structure of OXA-163. The four-amino
acid deletion and S212D substitution transform OXA-48 into
OXA-163 and change the substrate proﬁle of the enzyme. To
investigate the structural basis for the changes in speciﬁcity, the
X-ray crystal structure of OXA-163 was determined. The
asymmetric unit in the crystal consists of one dimer with the
same space group (P21) as the previously published crystal
structure of OXA-48.34 The mature OXA-163 enzyme consists
of 237 residues and has a two-domain fold typical of DBLs with
a globular α-domain and an α/β-domain with the active site
located between the two domains (Figure 1A). The active site
of OXA-163 forms a groove in the protein surface between the
two domains. The clefts of the groove are formed on one side
by the β5 strand and the N-terminus of helix α11, and on the
other by helices α5 and α6 and the Ω-loop (Figure 1A). The
three conserved motifs characteristic of the active site of DBLs
are outlined in Figure 1A. Motif I consists of the catalytic Ser70
as well as Thr71, Phe72, and carboxylated Lys73. The
carboxylate moiety attached to εN shows clear density (Figure
1B) in both monomers. Motif II contains residues Ser118,
Val119, and Val120 and is located on the loop between the α5
and α6 helices, while motif III consists of β5 strand residues
Lys208, Thr209, and Gly210. Lys208 interacts with Ser118
Table 2. Steady-State Kinetic Parameters of OXA-48 and OXA-163 for Cephalosporin and Carbapenem Substrates
OXA-48 OXA-163
substrate kcat (s
−1) Km (μM) kcat/Km (s
−1 M−1) kcat (s
−1) Km (μM) kcat/Km (s
−1 M−1)
nitroceﬁn 143 ± 24 36 ± 7 4.0 × 106 34 ± 2 19 ± 8 1.8 × 106
cephalothin 2.8 ± 0.1 140 ± 10 2.0 × 104 1.7 ± 0.1 3.4 ± 0.4 5.0 × 105
cefotaxime NMa >1000 4.7 × 103 14 ± 1 36 ± 11 3.8 × 105
ceftazidime NDb − − NM >1000 300
imipenem 2.7 ± 0.2 3.7 ± 0.7 9.0 × 105 0.004 ± 0.001 3.6 ± 1.0 1.1 × 103
meropenem 0.11 ± 0.01 6.0 ± 1.2 1.7 × 104 0.021 ± 0.001 5.3 ± 0.5 4.0 × 103
doripenem 0.066 ± 0.002 4.1 ± 0.6 1.6 × 104 0.018 ± 0.001 5.0 ± 0.4 3.6 × 103
aNot measurable. It was not possible to measure Vmax because of the high Km value.
bNot detected. No detectable hydrolysis with up to 5 μM
enzyme and 500 μM substrate.
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from motif II, and these residues have been suggested to play a
role in substrate binding and proton transfer in the acylation
reaction in DBLs.23 Overall, the OXA-163 structure is quite
similar to the OXA-48 structure34 (Figure 2A) with an rmsd of
0.271 Å for the matching Cα atoms. However, the β5−β6 loop
is shorter because of the 214-RIEP-217 deletion that results in
an expanded active-site cavity compared to that of OXA-48.
Like that of OXA-48, the quaternary structure of OXA-163 is
dimeric, which is not surprising because the residues at the
dimerization surface are identical.
A comparison of the active sites of OXA-48 and OXA-163
reveals several diﬀerences. (i) In OXA-48, the side chain of
Arg214 creates one side of the active site by forming an
electrostatic interaction with Asp159 positioned on the Ω-loop
(Figure 2A). In OXA-163, Arg214 is within the four-amino acid
deletion, which eliminates one boundary of the active site and
elongates the groove (Figure 2A). Arg214 has been suggested
to form electrostatic interactions with carbapenem substrates
that facilitate hydrolysis. This could explain the low activity of
OXA-163 toward carbapenems.34 Additionally, this expansion
of the active site of OXA-163 is consistent with the ability of
the enzyme to accommodate a larger substrate such as
ceftazidime. The hypothesis that Arg214 contributes to the
inability of OXA-48 to accommodate ceftazidime is also
supported by the observation that a shorter and uncharged
side chain at position 214 (R to S) results in an increase in
ceftazidime hydrolysis activity by OXA-232 (an OXA-48-like
enzyme).32 (ii) The 214-RIEP-217 deletion shortens and alters
the conformation of the β5−β6 loop in OXA-163 compared to
that in OXA-48 (Figure 2A). The position and length of this
loop have also been associated with eﬃcient deacylation in
carbapenem hydrolysis.34,39 The altered size and position of the
β5−β6 loop in OXA-163 may contribute to the reduced level of
hydrolysis of carbapenems by this enzyme (Table 2). At the
same time, this structural change widens the active site of OXA-
163 and provides extra space for the oxyimino group of
ceftazidime. (iii) The 214-RIEP-217 deletion also causes
displacement of Thr213, which in part contributes to the
enlargement of the active-site cavity of OXA-163. The
backbone, together with the side chain of Thr213, adopts a
diﬀerent conformation and moves away from the active site
(∼4 Å), creating a shorter β5−β6 loop (Figure 2A,B). Lys218,
which is now adjacent to Thr213, is also displaced farther from
the active site (5 Å). (iv) The newly introduced aspartate at
position 212 is also likely to contribute to the changes in OXA-
163 speciﬁcity. Compared to Ser212 in OXA-48, the Asp side
chain is pointed toward the β6 strand to form hydrogen bonds
with the -NH main-chain groups of Lys218 and Ile219 (Figure
2B). This draws the β5 strand main chain closer to the β6
strand and widens the active-site wall formed by the β5 strand.
(v) Finally, several water molecules that are part of a larger
interaction network that includes Ser70, Ser118, Thr209,
Tyr211, Thr213, and Arg250 in OXA-48 are misplaced or
missing in the OXA-163 structure (Figure 2C). This interacting
network in OXA-48 was suggested previously to be important
in the eﬃciency of the deacylation reaction for carbapenems.34
This observation is consistent with the large decrease in the
turnover number of OXA-163 for carbapenems (Table 2).
In summary, several spatial modiﬁcations in the active site of
OXA-163 ultimately expand the active site and rearrange the
inter-residue interaction network. The larger active site is
consistent with improved accommodation of ceftazidime and
the loss of critical interactions with carbapenem substrates,
resulting in an altered substrate proﬁle for OXA-163.
Crystal Structure of OXA-163 in the Presence of
Iodide. As described above, a second structure of OXA-163
was determined at 2.87 Å from crystals formed under a
condition that included 200 mM sodium iodide. The observed
asymmetric unit consists of four protein molecules (two
dimers) in a P1 space group. The dimer interface of the
structure with iodide is unchanged compared to that of native
OXA-163 and OXA-48 structures. The 2.87 Å resolution of the
structure with iodide clearly reveals the electron density of the
main-chain backbone. An exception was part of the loop
(residues 244−247) connecting the β7 strand and α-helix α11,
which did not show density and was not modeled in the ﬁnal
structure. Some of the solvent-exposed side chains, particularly
lysines and glutamates, were also not visualized. However, the
electron density for the active-site lysine 73, which acts as the
general base in its carboxylated form,20 was clearly resolved and
did not show an extension of the side chain, indicating the
carboxylate group was absent. Instead, an iodide ion was
observed in all four molecules in the asymmetric unit at the
Figure 1. Crystal structure of OXA-163. (A) Ribbon representation of
OXA-163 with secondary structural elements labeled. The three
conserved DBL motifs are shown with their respective residues as a
stick model: motif I in green (Ser70, Thr71, Phe72, and Lys73), motif
II in blue (Ser118, Val119, and Val120), and motif III in yellow
(Lys208, Thr209, and Gly210). (B) Active-site region of OXA-163.
The carboxylated side chain of the active-site residue Lys73 is shown
together with nearby interacting residues and water molecules.
Superimposed is the 2Fo − Fc simulated annealing diﬀerence map
calculated with phases from the ﬁnal reﬁned model and contoured at
the 2.5σ level. The carboxylate moiety is coordinated by Ser70,
Trp157, and, via a water molecule, Asn76. Red spheres represent the
two water molecules.
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location where the εN-carboxylate has been observed in other
crystal structures. Previously, a chloride ion has been observed
at this location in the crystal structures of wild-type OXA-10
and its V117T mutant.23,25
The two OXA-163 structures determined here are very
similar with an rmsd of 0.425 Å for their main-chain Cα atoms
(Figure 3A). However, the presence of iodide causes a series of
rearrangements in the active site, which ultimately leads to
distortion of the β5 strand and occlusion of the active-site
serine (Figure 3A). In the presence of iodide, Lys73 is not
carboxylated and adopts a conformation in which its side chain
points away from the active site and the bound iodide.
Similarly, the side chain of Lys208 is also dramatically shifted,
pointing away from the active site. In fact, Nζ of Lys73 in the
Figure 2. Comparison of the tertiary structures of OXA-48 at 1.9 Å and OXA-163 at 1.72-Å resolution. (A) Cα alignment of OXA-48 (blue) and
OXA-163 (lavender). The insets provide a detailed view of the β5−β6 loop region residues represented as a stick model with black dashes
representing interactions. Arg214 in OXA-48 forms an electrostatic interaction with Asp159 located on the Ω-loop. This interaction conﬁnes the
bottom boundary of the active-site cavity in OXA-48. In OXA-163, Arg214 is absent so the interaction is lost, resulting in an expanded active-site
cavity. (B) Stick representation of the β5−β6 loop region of OXA-48 and OXA-163. The OXA-163 residues that undergo the largest movement
compared to those of residues of OXA-48 are Tyr211, Thr213, and Lys218. The S212D substitution results in newly formed hydrogen bonds
between the Asp212 side chain and the -NH main chain of Lys218 and Ile219 represented as black dashed lines. (C) Active-site hydrogen bond
network in OXA-48 and OXA-163. Several water molecules exhibit altered positions or are missing in OXA-163 compared to OXA-48. Distances of
2.5−3.8 Å are shown as dashed black lines.
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OXA-163 iodide-bound structure occupies the position where
Nζ of Lys208 is found in the OXA-163 structure without iodide
and in OXA-48 (Figure 3A). Another major change observed in
the iodide-bound structure is with respect to Asp212, at the tip
of the β5 strand, which moves 5 Å toward the active site where
it hydrogen bonds with Ser70 and engages in electrostatic
interactions with Arg250 (Figure 3A). These rearrangements of
Lys73, Lys208, and Asp212 along with the newly formed
network of interactions involving Ser70, Asp212, and Arg250
result in the occlusion of the active site. Previous structural
studies of DBLs showed that Arg250 plays an important role in
binding and positioning of the carbapenem in the active site of
the enzyme.34,37,61 The rearrangements in the iodide-bound
structure result in a short β5 strand (three residues, 204−206),
which interacts with only the β4 strand. This is in contrast to
the OXA-163 structure without iodide, in which the β5 strand
is nine residues long (204−212), forming an antiparallel β-
sheet involving strands β4 and β6.
The iodide ion found in the active site of OXA-163 is located
in a hydrophobic pocket (Figure 3B). It is surrounded mainly
by nonpolar and aromatic moieties, with the exception of the
polar interaction with εNH of Trp157 (3.7 Å). The
hydrophobic interactions include the side-chain hydrocarbons
of Lys73 (3.8 Å), the aromatic component of Tyr123 (4.3 Å),
the side chain of Val120 (4.5 Å), the aromatic component of
Trp157 (4.5 Å), and the main-chain hydrocarbons of Ser70
(4.3 Å) and Ala69 (4.7 Å). The types of displacements
observed in the OXA-163 structure with iodide, including
alternative side-chain conformations and main-chain move-
ments, have been observed in several crystal structures that
accommodate an iodide ion in the proximity of a hydrophobic
region.62
Iodide ions have not previously been observed in the active
sites of OXA-enzyme crystal structures. However, chloride ions
have been identiﬁed in the active site of OXA-10.23,25 The
position of the chloride ion in the OXA-10 V117T mutant is
very similar to the iodide ion in the OXA-163 structure (Figure
3C). However, the iodide occupies a larger volume and results
in additional structural displacements in the active site
compared to those with chloride. Also, the interactions of the
chloride ion with OXA-10 are exclusively electrostatic, while the
iodide interactions are overwhelmingly hydrophobic. This is
possibly due to the diﬀerence in size between the two ion
species and their diﬀerent ability to tolerate a hydrophobic
environment. Chloride is smaller and can replace the
carboxylate group that is attached to Lys73 and thereby
maintain electrostatic interactions with the surrounding
residues. On the other hand, iodide is larger and cannot be
accommodated in the same location as the carboxylate without
expanding the cavity and rearranging the side chains of the
nearby residues. Additionally, iodide ions are more tolerant of a
hydrophobic environment than chloride ions and are found in
hydrophobic patches of proteins.62−64 Tyr141 from the YGN
conserved motif that has been implicated in chloride inhibition
of OXA-enzymes is 10 Å from the iodide in OXA-163,
suggesting it has a minimal role in the binding of the iodide.24
Figure 3. Alignment of the two OXA-163 structures and comparison of chloride and iodide ions in the active site of class D enzymes. (A) 1.72 Å
structure (lavender) and 2.87 Å structure with iodide (tan). Iodide is represented as a dark purple sphere with an arbitrary radius. The inset provides
a more detailed view of the residues (stick model) that undergo large conformational changes due to the presence of the iodide in the active site. In
the iodide structure, Asp212 exhibits an altered conformation that results in the formation of an electrostatic interaction with Arg250 (black dashed
line). Additionally, the Asp212 residue is within hydrogen bonding distance of the catalytic Ser70. The arrows represent the direction of the
rearrangements that occur in the iodide structure. (B) Iodide and its surrounding environment in the active site. In gray mesh, superimposed, is the
2Fo − Fc simulated annealing diﬀerence map calculated with phases from the ﬁnal reﬁned model and contoured at the 3.0σ level. In green mesh is the
anomalous diﬀerence map contoured at 5σ. Residues surrounding iodide are labeled and shown as stick models. (C) Overlay of OXA-10 (green)
inhibited by chloride (orange sphere) and OXA-163 (tan) inhibited by iodide (purple sphere). Iodide is larger than chloride and results in structural
rearrangements of the surrounding residues.
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Docking of Ceftazidime into the Active Sites of OXA-
48 and OXA-163. To further investigate why ceftazidime is
hydrolyzed by OXA-163 but not OXA-48, molecular docking of
ceftazidime was performed using Autodock Vena.54 The
protein structures used for docking were OXA-48 (PDB
entry 3HBR)34 and the OXA-163 structure without iodide
(PDB entry 4S2L). The same constraints were used for both
proteins (Materials and Methods). Each docking round gave
nine possible conformations, ranked from highest to lowest
predicted aﬃnity. It should be noted that all nine
conformations of ceftazidime in OXA-48 had the oxyimino
side chain of ceftazidime pointed toward Lys208 and the top of
the active site (Figure 4B). The hydrolysis of ceftazidime is not
mechanistically feasible from this conformation because the β-
lactam carbonyl oxygen is not in the proximity of the NH main-
chain atoms of Ser70 (5.3 Å) and Tyr211 (4.2 Å), which form
the oxyanion hole in DBLs. Also, the position of the carboxylate
group of ceftazidime does not form electrostatic interactions
with Thr209 and Arg250. These residues have been identiﬁed
previously to form strong electrostatic interactions with the
substrate carboxylate in crystal structures of OXA-enzymes.61,65
The dominance of this catalytically nonproductive conforma-
tion of ceftazidime in the docking results is due to the narrow
active-site cavity of OXA-48 that is conﬁned at the bottom by
Arg214 and the longer β5−β6 loop and Thr213. The narrow
cavity sterically hinders the formation of a more productive
conformation of the oxyimino side chain of ceftazidime.
In contrast, the highest-aﬃnity binding conformation
predicted for ceftazidime bound to OXA-163 has the substrate
in an orientation where the oxyimino side chain occupies the
bottom portion of the active-site cavity (Figure 4A).
Importantly, the carbonyl oxygen of the β-lactam ring of
ceftazidime is hydrogen-bonded to the main-chain nitrogens of
Ser70 and Tyr211 to form the oxyanion hole so that the
substrate is in a catalytically competent conformation. The
carboxylated Lys73 is on the other side of Ser70 and is not
within an interaction distance of the substrate. In addition, the
carboxylic acid moiety of the oxyimino group is within
hydrogen bonding distance of Oη of tyrosine 211 and Oγ of
serine 240. These interactions turn the imino-thiazole ring
toward the Ω-loop where it interacts with the main-chain CO
of leucine 158. This ﬂip in the conformation of ceftazidime in
the active site of OXA-163, compared to the conformation in
OXA-48, is allowed by the expanded cavity resulting from the
absence of the Arg214 side chain and the shorter β5−β6 loop.
The inability of ceftazidime to be docked in the active site of
OXA-48 in an orientation that is catalytically feasible is
consistent with the hypothesis that the active-site cavity of
OXA-48 is too small to ﬁt the bulky ceftazidime substrate.
OXA-163 also exhibits an increased kcat/Km for hydrolysis of
the oxyimino-cephalosporin cefotaxime compared to that of the
OXA-48 enzyme (Table 2). This is due to a large decrease in
Km from >1000 μM for OXA-48 to 36 μM for OXA-163. The
Km of cefotaxime for OXA-163 is also much lower than that
observed for ceftazidime. Molecular docking was therefore
performed with OXA-163 with cefotaxime for comparison with
the ceftazidime docking results. The docking results show that
cefotaxime ﬁts in the active site in a catalytically productive
pose with the β-lactam carbonyl oxygen present in the oxyanion
hole as observed for ceftazidime (Figure 4C). However,
cefotaxime is embedded deeper in the active-site cavity and
also has the aminothiazole ring ﬂipped 180° pointing toward
the solvent compared to ceftazidime. Although there is no X-
ray structural information available to examine the molecular
details of OXA-163 binding with cefotaxime and ceftazidime,
the docking studies suggest cefotaxime can assume a more
Figure 4. Docking results of ceftazidime with OXA-163 (lavender) and OXA-48 (light blue) and cefotaxime with OXA-163. The protein structures
are shown in surface representation, and the residues that interact with ceftazidime and cefotaxime are labeled and shown as sticks. Ceftazidime and
cefotaxime are shown as yellow and green sticks, respectively. The carboxylated Lys73, which is not within interaction distance of the substrate, is
also shown and is labeled KCX73. Black dashed lines represent hydrogen bonds. The top part of panel A shows the conformation with the lowest
binding energy of ceftazidime for OXA-163. The top part of panel B shows the conformation of ceftazidime with the lowest binding energy for OXA-
48. In OXA-48, the ceftazidime molecule is ﬂipped compared to the conformation in OXA-163. The docked conformation of ceftazidime in the
active site of OXA-48 is not consistent with catalysis. The top part of panel C shows the conformation with the lowest binding energy for OXA-163
with cefotaxime. The bottom parts show the oxyanion hole formed by Ser70 and Tyr211 and the interaction between the carboxylate group of
ceftazidime or ceftotaxime and Thr209 and Arg250. These interactions are altered in the docked conformation of ceftazidime in OXA-48 (panel B,
bottom) such that the β-lactam carbonyl interacts with Thr209 and Arg250 while Ser70 and Tyr211 interact with the carboxylate moiety.
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buried position in the active site, which may explain the lower
Km observed for cefotaxime hydrolysis by OXA-163 (Table 2).
Halogen Ion Inhibition of OXA-enzymes. The observa-
tion of an iodide ion and the associated rearrangement of key
active-site residues as well as the absence of carboxylated Lys73
in the crystal structure of OXA-163 in the presence of iodide
suggest that iodide ions inhibit the activity of the enzyme.
Considering the relative ability of iodide versus the other
halogens to enter a hydrophobic hydration shell66 and the
hydrophobic environment of the active site of DBLs, we predict
that iodide would be the most potent inhibitor among halogen
ions. To test these ideas, OXA-48 and OXA-163 were examined
for halogen ion inhibition. The substrates cephalothin (OXA-
48) and cefotaxime (OXA-163) were used to measure the
activity of the enzymes in the presence of halogen ions. It was
found that halogen ions inhibit both OXA-48 and OXA-163
with similar potencies (Table 3). The IC50 depends on the size
of the ion, the larger ions being better inhibitors. The crystal
structure of OXA-163 with iodide in the active site shows that
iodide is not within hydrogen bond distance of any of the
active-site residues except the εNH atom of Trp157 (Figure
3B). The inhibition assay results are consistent with the ability
of the halide ion to be accommodated in a hydrophobic
environment because the polar nature of the halogens decreases
with increasing size.67
To test whether halogens inhibit other class D enzymes that
are not members of the OXA-48-like family, inhibition assays
were performed with OXA-10 β-lactamase (Table 3). OXA-10
has been studied extensively, and it was the ﬁrst class D β-
lactamase with a determined X-ray structure.23 The sequence of
OXA-10 is 46% identical with that of OXA-48 and it is a
narrow-spectrum β-lactamase with high catalytic eﬃciency for
penicillins and early cephalosporins.33,39 As indicated in Table
3, the activity of OXA-10 is inhibited by halogens with a
potency similar to and on the same order of magnitude as those
of OXA-48 and OXA-163 where larger ions are better
inhibitors. Additionally, the iodide IC50 for OXA-10 is 4.2
mM, which is approximately 2.5-fold more potent than those of
both OXA-48 and OXA-163.
Taken together, the inhibition studies suggest that halogen
inhibition might be a property of all class D β-lactamases.
Although the IC50 values are in low millimolar range (for
iodide), the inhibition of carboxylation of Lys73 by halogens
may provide a starting point in the development of new β-
lactamase inhibitors given the fact that carboxylation of the
active-site lysine is an absolute requirement for the function of
all class D β-lactamases.
■ CONCLUSIONS
As multidrug resistant infections are on the rise, carbapenems
represent one of the last-resort antibiotics for the treatment of
these infections.16 Carbapenem-hydrolyzing class D β-lacta-
mases (CHDLs) inactivate carbapenems and confer resistance
to these drugs. One common CHDL that is widespread in
clinics is OXA-48.28,33 OXA-163 is a variant of OXA-48 with
attenuated catalytic eﬃciency for carbapenems that has gained
the ability to hydrolyze ceftazidime, expanding the ability of this
class of enzymes to hydrolyze β-lactams.32,35 Our structural
data suggest that in OXA-163 an enlargement of the active-site
cavity that allows this enzyme to accommodate ceftazidime
occurs. The enlargement of the active site provides a molecular
basis for the distinct substrate proﬁle of these two closely
related enzymes and, more broadly, shows that minor sequence
variations can profoundly alter the active site of an enzyme.
Lastly, we found that OXA-enzymes are inhibited by halogen
ions, with iodide being the most potent inhibitor. The structure
of OXA-163 in the presence of iodide shows that it changes the
position of key active-site residues and prevents carboxylation
of Lys73. This information may be utilized in the future
development of class D inhibitors considering that the
carboxylation of Lys73 is essential for the function of these
enzymes.
■ AUTHOR INFORMATION
Corresponding Author
*Department of Pharmacology, Baylor College of Medicine,
One Baylor Plaza, Houston, TX 77030. E-mail: timothyp@
bcm.edu. Telephone: (713) 798-5609.
Funding
This work was supported by National Institutes of Health
Grant AI32956 to T.P. B.V.V.P. acknowledges support from the
Robert Welch Foundation (Q1279). The Berkeley Center for
Structural Biology is supported in part by the National
Institutes of Health, National Institute of General Medical
Sciences, and the Howard Hughes Medical Institute. The
Advanced Light Source is supported by the Director, Oﬃce of
Science, Oﬃce of Basic Energy Sciences, of the U.S.
Department of Energy under Contract DE-AC02-05CH1123.
V.S. is supported by National Institute of Allergy and Infectious
Diseases Training Grant T32 AI55449.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
We thank Hiram F. Gilbert for discussions and comments on
the manuscript.
■ REFERENCES
(1) Pfeifer, Y., Cullik, A., and Witte, W. (2010) Resistance to
cephalosporins and carbapenems in Gram-negative bacterial patho-
gens. Int. J. Med. Microbiol. 300, 371−379.
(2) McKenna, M. (2013) Antibiotic resistance: The last resort.
Nature 499, 394−396.
(3) Lewis, K. (2013) Platforms for antibiotic discovery. Nat. Rev.
Drug Discovery 12, 371−387.
(4) Nordmann, P., Dortet, L., and Poirel, L. (2012) Carbapenem
resistance in Enterobacteriaceae: Here is the storm! Trends Mol. Med.
18, 263−272.
(5) Garbati, M. A., and Al Godhair, A. I. (2013) The growing
resistance of Klebsiella pneumoniae; the need to expand our
Table 3. IC50 Values of OXA-48, OXA-163, and OXA-10 for
Halogen Ions
IC50 (mM)
a
halide OXA-48 OXA-163 OXA-10
NaF 207 ± 11 216 ± 20 264 ± 20
NaCl 109 ± 12 97 ± 13 67 ± 10
NaBr 35 ± 7 29 ± 9 27 ± 6
NaI 14 ± 5 10 ± 4 4 ± 2
aValues and standard deviations were determined from three separate
experiments.
9
ht
tp
://
do
c.
re
ro
.c
h
antibiogram: Case report and review of the literature. African Journal of
Infectious Disease 7, 8−10.
(6) Guh, A. Y., Limbago, B. M., and Kallen, A. J. (2014)
Epidemiology and prevention of carbapenem-resistant Enterobacter-
iaceae in the United States. Expert Rev. Anti-Infect. Ther. 12, 565−580.
(7) Martinez-Martinez, L., and Gonzalez-Lopez, J. J. (2014)
Carbapenemases in Enterobacteriaceae: Types and molecular
epidemiology. Enfermedades Infecciosas y Microbiologiá Clińica 32
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